A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis.

A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis.
复制标题

DOI:
10.3389/fcell.2021.640476
复制
发表时间:
2021
影响因子:
5.5
通讯作者:
Zhang W
Zhang W
中科院分区:
生物学2区
文献类型:
--
作者:
Tian S;Yan L;Fu L;Zhang Z;Zhang J;Meng G;Zhang W

文献摘要

参考文献

相似文献

浆细胞样树突状细胞(pDC)是一种重要的免疫微环境成分。据报道,它们在连接适应系统和免疫系统方面起着至关重要的作用。然而,pDC在乳腺癌(BRCA)中的预后作用仍存在争议。在这项工作中,我们收集了大量的样本队列,并通过多组学数据分析进行了全面的调查,以揭示pDC与BRCA之间的关系。在BRCA患者中,pDC水平升高与生存期延长相关。高pDC丰度组的突变格局明显,体细胞拷贝数改变(SCNA)负担较低,瘤内异质性较低。此外,在高pDC组中观察到更敏感的免疫反应和化疗反应,这意味着高pDC丰度的患者可以从化疗和免疫治疗联合中获益。综上所述,pDC丰度与BRCA患者的总生存期(OS)呈正相关。我们确定了pDC丰度的BRCA患者的分子谱。我们的研究结果可能有助于帮助免疫疗法的发展和阐明BRCA的精确治疗。
Plasmacytoid dendritic cells (pDC) are an essential immune microenvironment component. They have been reported for crucial roles in linking the adaptive and immune systems. However, the prognostic role of the pDC in breast cancer (BRCA) was controversial. In this work, we collected large sample cohorts and did a comprehensive investigation to reveal the relationship between pDC and BRCA by multiomics data analysis. Elevated pDC levels were correlated with prolonged survival outcomes in BRCA patients. The distinct mutation landscape and lower burden of somatic copy number alterations (SCNA) and lower intratumoral heterogeneity were observed in the high pDC abundance group. Additionally, a more sensitive immune response and chemotherapies response were observed in the high pDC group, which implicates that patients with high pDC abundance can be benefited from the combination of chemotherapy and immunotherapy. In conclusion, the correlation between pDC abundance and BRCA patients’ overall survival (OS) was found to be positive. We identified the molecular profiles of BRCA patients with pDC abundance. Our findings may be beneficial in aiding in the development of immunotherapy and elucidating on the precision treatment for BRCA.
DOI: 10.1016/j.oraloncology.2012.09.007
发表时间: 2013-03
期刊: ORAL ONCOLOGY
影响因子: 4.8
作者:
Mroz, Edmund A.;Rocco, James W.
通讯作者: Rocco, James W.
DOI: 10.1371/journal.pone.0001195
发表时间: 2007-11-21
期刊: PloS one
影响因子: 3.7
作者:
Hoshida Y;Brunet JP;Tamayo P;Golub TR;Mesirov JP
通讯作者: Mesirov JP
DOI: 10.1186/s12967-016-0905-x
发表时间: 2016-05-28
影响因子: 7.4
作者:
Bailur, Jithendra Kini;Gueckel, Brigitte;Pawelec, Graham
通讯作者: Pawelec, Graham
DOI: 10.4161/onci.23185
发表时间: 2013-03-01
期刊: Oncoimmunology
影响因子: 7.2
作者:
Faget J;Sisirak V;Blay JY;Caux C;Bendriss-Vermare N;Ménétrier-Caux C
通讯作者: Ménétrier-Caux C
DOI: 10.1593/neo.132076
发表时间: 2014-02-01
期刊: NEOPLASIA
影响因子: 4.8
作者:
Chu, Jenny E.;Xia, Ying;Allan, Alison L.
通讯作者: Allan, Alison L.